Navigation Links
Rib-X Pharmaceuticals to Present at the 49th ICAAC
Date:9/10/2009

ept data on our novel chemical class Gram-negative program."

About Rib-X Pharmaceuticals, Inc.

Rib-X Pharmaceuticals, Inc. is a product-driven small molecule drug discovery and development company focused on the structure-based design of new classes of antibiotics. The Company's underlying drug discovery engine capitalizes on its proprietary high-resolution crystal structure of the ribosome, which performs an essential role in protein synthesis. Many known, commercially valuable antibiotics exert their effects by binding to the bacterial ribosome. The Company's integrated research strategy, which combines state-of-the-art, proprietary computational analysis, X-ray crystallography, medicinal chemistry, microbiology and biochemistry, allows it to rapidly synthesize new agents designed to avoid typical antibiotic resistance mechanisms. Rib-X's iterative intelligent engine has yielded several distinctive new antibiotics that can be used for the treatment of either community- or hospital-acquired infections. In addition to Rx-04, Rib-X has successfully completed Phase 2 trials with delafloxacin (RX-3341), a broad spectrum fluoroquinolone with potent activity against quinolone resistant Gram-positive bacteria including MRSA. Radezolid (RX-1741), an oxazolidinone that was discovered at Rib-X, as an oral/IV agent for treatment of serious Gram-positive infections has completed two Phase 2 trials and the Rx-02 discovery program which is focused on developing an IV/oral macrolide active against methicillin-resistant S. aureus, multidrug-resistant Streptococcus pneumoniae and S. pyogenes. Both delafloxacin and radezolid are currently in late stage clinical trials.

For more information on the Rib-X mission and the pipeline, please visit the Company website at www.rib-x.com.

For further
'/>"/>

SOURCE Rib-X Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Rib-X Pharmaceuticals Antibiotic Drug Discovery Platform Discovers Novel Compounds with Activity Against Key Multiple Drug Resistant Gram-negative Bacteria
2. Rib-X Pharmaceuticals Reports Positive Phase 2 Study Results for Radezolid in Community-Acquired Pneumonia
3. Rib-X Pharmaceuticals, Inc. Appoints Dr. Russell Greig to Board of Directors
4. Rib-X Pharmaceuticals Announces Presentations at the 19th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
5. Rib-X Pharmaceuticals Announces Positive Phase 2 Study Results for Delafloxacin and a $25 Million Financing
6. Rib-X Pharmaceuticals to Present at the 2008 ICAAC/IDSA Joint Meeting
7. Rib-X Pharmaceuticals, Inc. Announces Formation of Clinical Advisory Board
8. Rib-X Pharmaceuticals to Present at Cambridge Healthtech Institutes 2nd Annual Challenge of Antibacterial Development Conference
9. Rib-X Pharmaceuticals Initiates Two Phase 2 Studies for Novel Antibiotic Compound RX-1741
10. Cadence Pharmaceuticals to Present at Two Investment Conferences During the Month of September 2009
11. Dont Wait to Innovate: Future Pharmaceuticals Magazine Releases Its Issue on Innovation in IT, Cell-Based Therapy and Supply Chains
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2015)... , ... July 25, 2015 , ... ... its refractometer series. It precisely checks and adjusts the surface temperature of the ... , In the pharmaceutical industry, data traceability and documentation are key requirements. It ...
(Date:7/24/2015)... 2015 Equity Research Institute has ... (NASDAQ: PDLI ), Arena Pharmaceuticals Inc. (NASDAQ: ... Biotherapeutics Inc. (NASDAQ: NWBO ), and Acorda Therapeutics ... PDL BioPharma can be accessed at https://www.EquityResearchInstitute.com/reports?keyword=PDLI ... at 5,146.41, down 0.49%, the Dow Jones Industrial Average ...
(Date:7/24/2015)... BEIJING , July 24, 2015 Origin Agritech ... supplier of crop seeds in China , ... third quarter fiscal year 2015 ended June 30, 2015, before ... The Company will host a teleconference on August 5th, 2015, ... time to discuss the results. To participate in ...
(Date:7/24/2015)... , ... July 24, 2015 ... ... class-leading frozen sample management solution, indispensable to any modern scientific or pharmaceutical ... has a user-friendly interface. Users know precisely where a sample is located ...
Breaking Biology Technology:It’s T-Time for Refractometers: On-site Temperature Check Now Available 2Biotechnology Stocks in Motion -- PDL BioPharma, Arena Pharma, StemCells, Northwest Biotherapeutics, and Acorda Therapeutics 2Biotechnology Stocks in Motion -- PDL BioPharma, Arena Pharma, StemCells, Northwest Biotherapeutics, and Acorda Therapeutics 3Biotechnology Stocks in Motion -- PDL BioPharma, Arena Pharma, StemCells, Northwest Biotherapeutics, and Acorda Therapeutics 4Biotechnology Stocks in Motion -- PDL BioPharma, Arena Pharma, StemCells, Northwest Biotherapeutics, and Acorda Therapeutics 5Origin Agritech Limited to Announce Third Quarter Fiscal 2015 Unaudited Financial Results on August 5th, 2015 2Origin Agritech Limited to Announce Third Quarter Fiscal 2015 Unaudited Financial Results on August 5th, 2015 3RURO, Inc. Partners with Integrated Systems Engineering to Provide Comprehensive LIMS Software to Biobanks 2RURO, Inc. Partners with Integrated Systems Engineering to Provide Comprehensive LIMS Software to Biobanks 3RURO, Inc. Partners with Integrated Systems Engineering to Provide Comprehensive LIMS Software to Biobanks 4
... In Lawsuit, CHICAGO, May 14 Last month ... on behalf of Davenport,Iowa resident, Mark Scott who suffered ... 30, 2007. The complaint was filed On April 1, ... Law Group and alleges that,Melissa Scott,s untimely death was ...
... Also Augments Senior Management Team with Recent Strategic Hires ... ... Rico, May 14 Triple-S,Management Corporation (NYSE: GTS ) today announced ... investigator for the Children,s Oncology Group and,the Dana Farber Acute Lymphoblastic Leukemia ...
... Ill., May 14 Sagent Pharmaceuticals, Inc.,a privately-held ... US$20,000 to the American Red Cross to assist ... "As a part of the global community, we ... of the Sichuan province," said Jeffrey M. Yordon,chief ...
Cached Biology Technology:Iowa Resident Dies After Using Contaminated Blood Thinner 2Iowa Resident Dies After Using Contaminated Blood Thinner 3Triple-S Management Corporation Appoints New Non-Executive Chairman to Board; Adds New Director 2
(Date:7/8/2015)... 2015  Trovagene, Inc. (NASDAQ: TROV ), ... the launch of a study that aims to ... (PCM) technology for predicting response to treatment in ... of the novel immunotherapy agents Yervoy® (ipilumumab), a ... The 50-patient study will be led by researchers ...
(Date:7/2/2015)... 25, 2015 Research ... of the "Natural Language Processing Market by ... OCR, Pattern & Image Recognition) - Worldwide Forecast ... The key vendors occupying the market are ... Microsoft Corporation, NetBase Solutions, SAS Institute Inc., Verint ...
(Date:6/29/2015)... 2015 Research and Markets( ... "Latin America Biomedical Sensors Market - Growth, Trends & ... The Latin America Biomedical Sensors market is estimated at ... over the period 2014-2020 The near future ... genetic formulation of each individual. These sensors can be ...
Breaking Biology News(10 mins):Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4Natural Language Processing Market by Type (Rule-Based, Statistical, and Hybrid), Technologies (Recognition, IVR, OCR, Pattern & Image Recognition) - Worldwide Forecast to 2020 2Latin America Biomedical Sensors Market Report 2015-2020 2
... people regain strength and normal use of affected hands ... California, Irvine study. , Stroke patients with ... release objects after therapy sessions using the Hand-Wrist Assisting ... residual weakness and reduced function of the right hand, ...
... The results of a new study suggest that bacteria ... illness can turn the genes that make them infectious ... Yersinia pestis and E. coli, do this may one ... of these genes, thereby making the bacteria harmless, said ...
... than what scientists had been assuming. A new study, appearing ... Chemistry, provides new information on the inner workings of cells ... make livers regrow in patients with liver diseases such as ... one of the few organs in the body that can ...
Cached Biology News:Robotic therapy helps restore hand use after stroke 2Robotic therapy helps restore hand use after stroke 3Bacteria control how infectious they become, study finds 2Bacteria control how infectious they become, study finds 3Liver regeneration may be simpler than previously thought 2Liver regeneration may be simpler than previously thought 3
mCD-1 10 transcription reactions...
Recombinant Rhesus Macaque IFN-alpha...
... 500 g protein ... mouse whole cell lysate; Abelson transformed ... provided as Western blotting positive control, ... freezing and thawing should be minimized, ...
The epitope is specific for TASK and is not present in any other known proteins tested so far.,SPECIES REACTIVITIES: The epitope is also highly conserved between mouse and rat (17/18 residues iden...
Biology Products: